Get the Stockscreener App
3.71
0.27%
+0.010
Mural Oncology Plc stock is currently priced at $3.71, with a 24-hour trading volume of 32,544.
It has seen a +0.27% increased in the last 24 hours and a -23.51% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.71 pivot point. If it approaches the $3.63 support level, significant changes may occur.
Previous Close:
$3.70
Open:
$3.71
24h Volume:
32,544
Market Cap:
$63.29M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.06%
1M Performance:
-23.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1D Range:
$3.67
$3.805
52W Range:
$3.44
$6.00
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Mural Oncology Plc Stock (MURA) Latest News
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
GlobeNewswire Inc.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
About Mural Oncology Plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.
0.49%
0.40%
Cap:
|
Volume (24h):